This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing Avidity's del-desiran as a potential therapy to treat DM1 (Myotonic Dystrophy Type 1)
Ticker(s): RNA, DYNWho's the expert?
Institution: Advocate Health
- Pediatric neurologist affiliated with Advocate Health
- Clinical Interests include Tourette's Syndrome, tic disorders, seizure disorders, neurophysiology, neuromuscular disease, behavioral therapy/problems, developmental and behavioral disorders
- Sees 20+ DM1 patients and is familiar with investigational agents in DM1
Are You Interested In These Questions?
Slingshot Insights Explained
- Call Date
- Jan 22, 2025
- Call Time
- 01:00 PM EST
Wall Street Time
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
